Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Refractory Multiple Myeloma Clinical Trial

— ClaSPd  

Official title:

A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04843579
• Other study ID #: 20-12023093
• Status: Terminated
• Phase: Phase 2
• Start date: December 29, 2021
• Est. completion date: December 30, 2022

Study information

• Verified date: October 2023
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: December 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Written informed consent in accordance with federal, local, and institutional guidelines.

• Age =18 and <75 years at the time of informed consent.

• Confirmed diagnosis of multiple myeloma

• Symptomatic multiple myeloma per IMWG guidelines.

• Measurable disease as defined by at least one of the following: a. Serum M-protein = 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA, and/or b. Urinary M-protein excretion at least 200 mg/24 hours, and/or c. Serum FLC = 100 mg/L, provided that FLC ratio is abnormal, and/or d. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement (e.g., for IgA MM), then quantitative Ig levels by nephelometry or turbidimetry are acceptable.

• Relapsed and refractory multiple myeloma with documented evidence of PD after achieving at least SD for = 1 cycle during a previous MM regimen (i.e., relapsed MM), and = 25% response (i.e., patients never achieved = MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM).

• Previously received one to four prior lines of therapy and be pomalidomide-naïve.

Exclusion Criteria:

• Documented active systemic light chain amyloidosis.

• Active plasma cell leukemia.

• Eastern Cooperative Oncology Group (ECOG) Performance Status greater than 2.

• Persistent non-hematological toxicity (except for peripheral neuropathy) from a prior treatment which has not resolved to at least Grade 2 or better by Cycle 1 Day 1 (C1D1).

• Severe hepatic dysfunction with either: a. Total bilirubin > 2x ULN (> 3x ULN in subjects with Gilbert's syndrome [hereditary indirect hyperbilirubinemia]), and/or b. AST and/or ALT > 2.5x ULN

• Severe renal dysfunction with an estimated creatinine clearance of < 15 mL/min calculated using the Cockcroft and Gault formula.

• Impaired hematopoietic function with either: a. White blood cell count < 1,500/mm3, and/or b. Absolute neutrophil count < 1000/mm3, and/or c. Hemoglobin < 8.0 g/dL, and/or d. Platelet count < 100,000/mm3 (for patients in whom = 50% of bone marrow nucleated cells are plasma cells, platelets = 75,000/mm3 are acceptable).

• Blood (or blood product) transfusions or blood growth factors within 7 days of C1D1. Use of hematopoietic growth factor support is acceptable, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim). However, patients must be platelet transfusion independent for > 1 week in order to be enrolled in the study.

• Radiation, chemotherapy or immunotherapy, or any other anticancer therapy within 2 weeks prior to C1D1, or radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures, as well as for pain management.

• Patients with history of spinal cord compression with residual paraplegia.

• Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1.

• Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1.

• Active graft versus host disease after allogeneic stem cell transplantation.

• Life expectancy < 3 months.

• Major surgery within 4 weeks prior to C1D1.

• Active, unstable cardiovascular function with either: a. Symptomatic ischemia, b. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), c. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class = 3, d. Myocardial infarction (MI) within 6 months prior to C1D1, or e. Screening 12-lead ECG showing a baseline QT interval as corrected by Bazett's formula (QTc) > 470 msec

• Uncontrolled active hypertension

• Venous thromboembolism within 6 months prior to C1D1 or a known inherited thrombophilia

• Inability to receive either prophylactic or therapeutic anticoagulation as determined appropriate by the Investigator

• Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to C1D1

• Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment

• Currently pregnant or breastfeeding. Lactating females must agree not to breast feed while receiving selinexor, pomalidomide and/or clarithromycin

• A serious psychiatric or medical condition which, in the opinion of the Investigator, could interfere with treatment

• Hypersensitivity or contraindication to selinexor, pomalidomide, dexamethasone and/or clarithromycin

• Prior exposure to a SINE compound, including selinexor

• Concomitant use of any strong CYP3A4 and/or CYP1A2 inhibitors (see Appendix 1)

• Unable to obtain commercial clarithromycin, pomalidomide and dexamethasone through a regular and/or specialty pharmacy.

• Unable or unwilling to register into the mandatory POMALYST REMSTM program and comply with its requirements.

• Male and female patients unwilling or unable to use effective methods of contraception throughout the study and for three months following the last dose. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Note that female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.

Related Conditions & MeSH terms

• Multiple Myeloma
• Myeloma
• Myeloma Multiple
• Neoplasms, Plasma Cell
• Refractory Multiple Myeloma

Intervention

Drug:
• Selinexor
Given as 60 mg oral capsule
• Clarithromycin
Given as 500 mg oral capsule
• Pomalidomide
Given as 4 mg oral capsule
• Dexamethasone
Given as 40 mg oral capsule

Locations

Country	Name	City	State
United States	NewYork-Presbyterian Brooklyn Methodist Hospital	Brooklyn	New York
United States	Weill Cornell Medicine - Multiple Myeloma Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Karyopharm Therapeutics Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Overall Response Rate of Partial Response or Better	ORR is defined as participants who experience a partial response, very good partial response, complete response, or stringent complete response per International Myeloma Working Group Criteria (IMWG) 2016 criteria. Complete Response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow aspirates. Stringent Complete Response is defined as complete response as noted previously plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry. Partial Response is =50% reduction of serum M-protein plus reduction in 24 hour urinary M-protein by =90% or to <200 mg per 24 h. Very Good Partial Response is serum and urine M-protein detectable by immunofixation but not on electrophoresis or =90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hr.	Until disease progression; the maximum time any participant was followed for ORR was 287 days
Secondary	Number of Participants With Adverse Events	Adverse events will be determined by Events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The frequency of adverse events will be collected in tabular summary from when a participant consent to study until end of study or patient participant starts a new treatment.	Adverse events were collected from time of informed consent until 30 days after the last day of study drug administration for each participant. The maximum period that AEs were collected for a participant was 300 days.